Important Differences between Topoisomerase-I and -II Targeting Agents

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 965-966

  Banerji, Shantanu ^a   Los, Marek ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Mitoxantrone; Reactive oxygen species (ros); Topoisomerase targeting agents; Topotecan; X2HS

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); H2AFX PROTEIN, HUMAN; HISTONE; MITOXANTRONE; PROTEIN SERINE THREONINE KINASE; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN;

CELL CULTURE; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NOTE; PHOSPHORYLATION;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HISTONES; HUMANS; MITOXANTRONE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 33846375151     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.3274     Document Type: Note

References (20)

1. Wall MEW, M.C.; Cook C.E.; et al. Plant antitumor agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acumunita. J Am Chem Soc 1966; 88:3888-90.
2. Sparreboom AZ, W.C. Topoisomerase I-Targeting Drugs. In: Chabner BAL, D.L., editor. Cancer Chemotherapy & Biotherapy: Principles and Practice. 4th ed. Philadelphia: Lippincot Williams & Wilkins; 2006.
3. Takimoto CH. Topoisomerase Interactive Agents. In: Devita VTH, S.; Rosenberg, S.A., editor. CANCER: Principles & Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
4. Huang X, Kurose A, Tanaka T, Traganos F, Dai W, Darzynkiewicz Z. Activation of ATM and Histone H2AX Phosphorylation Induced by Mitoxantrone But Not by Topotecan is Prevented by the Antioxidant N-acetyl-L-Cysteine. Cancer Biol Ther 2006; 5:959-64.
5. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260:14873-8. (Pubitemid 16211028)
6. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48:1722-6.
7. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3:430-40. (Pubitemid 34685700)
8. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49:5077-82. (Pubitemid 19239347)
9. Pommier YG, F. Topoisomerase II Inhibitors: The Epipodophyllotoxins, Acridines, and Ellipticines. In: Chabner BAL, D.L., editor. Cancer Chemotherapy & Biotherapy: Principles and Practice. 4th ed. Philadelphia: Lippincot Williams & Wilkins; 2006.
10. Doroshow JH. Anthracyclines and Anthracenediones. In: Chabner BAL, D.L., editor. Cancer Chemotherapy & Biotherapy: Principles and Practice. 4th ed. Philadelphia: Lippincot Williams & Wilkins; 2006.
11. Abraham RT, Tibbetts RS. Cell biology. Guiding ATM to broken DNA. Science 2005; 308:510-1. (Pubitemid 40570574)
12. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433-9.
13. Modesti M, Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol 2001; 11:R229-32. (Pubitemid 32241511)
14. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001; 276:42462-7.
15. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res 2003; 63:4347-50. (Pubitemid 36951002)
16. Tanaka T, Kurose A, Huang X, Dai W, Darzynkiewicz Z. ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis. Cell Prolif 2006; 39:49-60.
17. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004; 279:53272-81. (Pubitemid 40051831)
18. Lu HR, Zhu H, Huang M, Chen Y, Cai YJ, Miao ZH, Zhang JS, Ding J. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 2005; 68:983-94. (Pubitemid 41345790)
19. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005; 65:3671-81. (Pubitemid 40616344)
20. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004; 103:4659-65. (Pubitemid 38745999)